PatientsVille.com Logo


Ursodiol Medical Research Studies

Up-to-date List of Ursodiol Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Ursodiol Medical Research Studies

Rank Status Study
1 Not yet recruiting The Effect of Ursodeoxycholic Acid in Liver Functional Restoration of Patients With Obstructive Jaundice
Condition: Obstructive Jaundice
Intervention: Drug: Ursodeoxycholic Acid
Outcome Measures: Liver functional restoration;   To assess that in which functional parameters of the liver, treatment with UDCA will have greater impact
2 Recruiting Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin
Condition: Type 2 Diabetes Mellitus
Intervention: Drug: Ursodiol
Outcome Measures: Reduction in area above basal (AAB) for Glucose;   Fasting glucose;   Insulin sensitivity calculated by the oral minimal model;   Gastric emptying of liquids (T1/2);   Gastric emptying of solids (T1/2);   Weight change, kg;   Insulin secretion calculated by the oral minimal model;   24 hour colonic geometric center
3 Recruiting Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)
Condition: Primary Biliary Cirrhosis
Interventions: Drug: budesonide;   Drug: budesonide placebo
Outcome Measures: Rate of patients without treatment failure after 3 years of treatment;   course of pruritus;   course of fatigue;   course of Mayo Risk score;   bone mineral density
4 Unknown  Cholestatic Drug-induced Liver Injury
Condition: Hepatitis, Toxic
Interventions: Drug: Ursodeoxycholic Acid;   Drug: Placebo
Outcome Measure: severe degree drug-induced liver injury, fatality or liver transplantation
5 Recruiting Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis
Condition: Primary Sclerosing Cholangitis
Intervention: Drug: ursodeoxycholic acid (UDCA) withdrawal and reinstitution
Outcome Measures: The primary outcome will be the change in alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT) or biomarkers for inflammation in study subjects at baseline compared to the end of Phase III (UDCA discontinuation) of the study.;   A secondary outcome will be the change in ALT, GGT or biomarkers for inflammation in study subjects at the end of Phase III (UDCA discontinuation) compared to the end of Phase IV (UDCA reinstitution) of the study.
6 Recruiting Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease
Conditions: Polycystic Liver Disease (PLD):;   Polycystic Kidney, Autosomal Dominant;   Polycystic Liver Disease
Intervention: Drug: Ursodeoxycholic Acid
Outcome Measures: Effect of UDCA on total liver volume;   Effect of UDCA-therapy on absolute total liver volume;   Effect of UDCA on gastro-intestinal symptoms measured by a GI-questionnaire;   Effect of UDCA on health related quality of life as measured by SF-36;   Proportion of patients with any reduction in total liver volume after 24 weeks;   Effect of UDCA on abslute total kidney volume
7 Unknown  Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases
Conditions: Type 2 Diabetes Mellitus;   Chronic Liver Disease
Interventions: Drug: UDCA;   Drug: Sitagliptin
Outcome Measures: the difference of haemoglobin A1c (HbA1c) and glycoalbumin (GA);   Change from Baseline in Glucagon-like peptide-1 (GLP-1) response to lipid meal test (fat 55%);   Change from Baseline in energy expenditure;   Change from Baseline in fasting plasma glucose level;   change from baseline in autonomic nerve function
8 Unknown  Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity
Conditions: Colorectal Cancer;   Liver Metastases;   Irradiation Damage;   Radiation Induced Liver Disease
Interventions: Drug: Pentoxifylline;   Drug: Ursodeoxycholic Acid;   Drug: Enoxaparin
Outcome Measures: HDR-brachytherapy isodose (measured in Gy) that corresponds to the metastases without enhancement of Gd-EOB-DTPA in MR imaging using an axial T1 THRIVE sequence.;   HDR-brachytherapy isodose (measured in Gy) that corresponds to the irradiated liver tissue without enhancement of Gd-EOB-DTPA in MR imaging using an axial T1 THRIVE sequence.;   Correlation between the HDR brachytherapy isodose that corresponds to damaged live tissue as defined by missing Gd-EOB-DTPA enhancement in MR imaging and liver-specific laboratory values.;   Quality of live.;   Safety of the study drugs.
9 Recruiting Safety and Efficacy Study of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis
Conditions: Transthyretin Amyloidosis;   Cardiomyopathy
Interventions: Drug: Doxycycline;   Drug: Ursodeoxycholic acid
Outcome Measures: The efficacy on serum N terminal proBNP (NT-proBNP);   Modified Body Mass Index (mBMI) reduction;   Increase of septum thickness;   Neurologic Kumamoto Scale;   Number of patients with adverse events;   Blood work for potential drug-related adverse events
10 Unknown  Ursodeoxycholic Acid And Cholestasis Of Pregnancy
Condition: Intrahepatic Cholestasis of Pregnancy
Interventions: Drug: Ursodeoxycholic Acid;   Drug: Placebo
Outcome Measures: Number of participants with preterm delivery (before week 37);   Pruritus on the Visual Analogue Scale;   Transaminases;   Bile Acids;   Fetal movement count;   Number of pregnancies with cardiotocography suggestive of fetal stress;   APGAR index;   Number of pregnancies with Green stained amniotic fluid
11 Recruiting Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis
Conditions: Primary Biliary Cirrhosis;   PBC
Interventions: Drug: LUM001;   Drug: Placebo;   Drug: Ursodeoxycholic Acid
Outcome Measure: Efficacy
12 Not yet recruiting Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis
Condition: Primary Biliary Cirrhosis
Intervention: Biological: abatacept
Outcome Measures: Biochemical Response;   Safety;   Absolute and percent change in alkaline phosphatase;   Absolute and percent change in alanine transferase (ALT);   Liver stiffness measured by magnetic resonance elastography;   Quality of life;   Anti-abatacept titers;   Abatacept levels
13 Recruiting The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Short Bowel Syndrome Patients
Condition: Short Bowel Syndrome
Intervention: Drug: ursodeoxycholic acid
Outcome Measures: The biochemical indicator of patients' liver function during oral UDCA or placebo;   the changs of composition of serum bile acid after oral UDCA or placebo;   The changs of the level of fibroblast growth factor 19(FGF19) in the serum
14 Unknown  Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis
Condition: Cystic Fibrosis
Interventions: Drug: tauroursodeoxycholic acid;   Drug: Ursodiol
Outcome Measure:
15 Recruiting Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis
Condition: PBC
Interventions: Drug: Bezafibrate;   Drug: placebo
Outcome Measures: Percentage of patients with complete biochemical response.;   Percentage of patients having biological or clinical adverse reaction.;   Percentage of patients having complete biochemical response.;   Evolution of the pruritus.;   Assessment of the fatigue and the quality of life.;   Evolution of liver fibrosis surrogate markers.;   Evolution of the portal hypertension markers.;   Histological evolution: Histopathological examination of biological sample before enrolment and at the end of the study.;   Evolution of the biological markers of the hepatic function or being in the usual prognostic scores (Mayo, Child, MELD).;   Survival without transplantation and hepatic impairment.
16 Recruiting A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus
Condition: Cholestasis, Intrahepatic
Interventions: Drug: GSK2330672;   Drug: Placebo;   Drug: Ursodeoxycholic acid
Outcome Measures: Safety and tolerability assessment following repeat doses of GSK2330672;   Tolerability assessment using Gastrointestinal Symptom Rating Scale (GSRS).;   Fecal occult blood testing;   Steady-state PK assessment of UDCA and its taurine and glycine conjugates taurodeoxycholic acid (TUDCA) and glycoursodeoxcholic acid (GUDCA);   Plasma GSK2330672 PK assessment;   Measurement of serum profiles of total bile acid concentrations and 7-alpha hydroxy-4-cholesten-3-one (C4);   Subject reported outcomes - daily pruritus 0 to 10 pt scale.;   Subject reported outcomes - 5D-itch scale;   Patient reported outcomes PBC-40 quality of life (QoL) scale.
17 Unknown  Study of Bile Acids in Patients With Peroxisomal Disorders
Conditions: Infantile Refsum's Disease;   Zellweger Syndrome;   Bifunctional Enzyme Deficiency;   Adrenoleukodystrophy
Interventions: Drug: chenodeoxycholic acid;   Drug: cholic acid;   Drug: Ursodiol
Outcome Measure:
18 Unknown  Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis
Condition: Primary Biliary Cirrhosis
Interventions: Biological: Biological: mesenchymal stem cell;   Drug: ursodeoxycholic acid
Outcome Measures: serum level of alkaline phosphatase;   histological changes in liver biopsies;   Serum levels of TNF-alpha;   changes in fatigue;   The occurrence of cirrhosis and its complications;   Serum levels of Interleukin;   changes in pruritus severity
19 Recruiting Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC
Conditions: MonoMAC;   Myelodysplastic Syndrome;   Immunodeficiency
Interventions: Procedure: Reduced-Intensity Hematopoietic Stem Cell;   Drug: Fludarabine;   Procedure: Total Body Irradiation (TBI);   Drug: Filgrastim;   Drug: Sirolimus;   Drug: Tacrolimus;   Drug: Ursodiol
Outcome Measure: Determine efficacy, whether reduced-intensity allogeneic HSCT results in engraftment and restores normal hematopoiesis by day +100 in patients with MonoMAC. Determine the safety of this HSCT regimen in MonoMAC including transplant related toxici...
20 Recruiting Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis
Condition: Primary Biliary Cirrhosis
Interventions: Biological: NGM282;   Biological: Placebo
Outcome Measures: Absolute change in plasma ALP from Baseline to Day 28;   Absolute change in bilirubin from Baseline to Day 28

These studies may lead to new treatments and are adding insight into Ursodiol etiology and treatment.

A major focus of Ursodiol research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Ursodiol